2011 Fiscal Year Final Research Report
Development of auto-IAP-antibody screening array for diagnosing cancer patients.
| Project/Area Number |
21390183
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Laboratory medicine
|
|---|
| Research Institution | Sapporo Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KOBAYASHI Daisuke 札幌医科大学, 医学部, 講師 (50295359)
KURIBAYASHI Kageaki 札幌医科大学, 医学部, 講師 (50381257)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Keywords | 腫瘍検査学 |
|---|
| Research Abstract |
The inhibitor of-apoptosis(IAP) family proteins are shown to be advantageous to cancer in many circumstances, including carcinogenesis, promotion, and therapy resistance. In this study, we focused on expression of anti-survivin, anti-livin and anti-XIAP antibodies as tumor markers in patients with colorectal polyp and cancer, and developed the screening array that can be automated. We compared positivity of anti-survivin, anti-livin, and anti-XIAP antibodies with existing tumor markers, including carcinoembryonic antigen(CEA), carbohydrate antigen 19-9(CA19-9), and anti-p53 antibody. So far, positivity of anti-livin antibody in patients with colorectal cancer was low at 2. 4%; positivity of CEA, CA19-9, and anti-p53 antibody were 39. 8%, 21. 6%, and 25. 0%, respectively. Positivity of anti-survivin and anti-XIAP antibodies was higher than other tumor markers at 37. 5% and 36. 3%, respectively. Furthermore, expression of anti-survivin and anti-XIAP antibodies was found not only in patients with early stage colorectal cancer but also in patients with colorectal polyps.
|
Research Products
(19 results)
